RT Journal Article
SR Electronic
T1 ▾ Pergolide (celance) – a third dopamine agonist
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 79
OP 79
DO 10.1136/dtb.29.20.79
VO 29
IS 20
YR 1991
UL http://dtb.bmj.com/content/29/20/79.1.abstract
AB Pergolide (Celance – Lilly) is structurally related to bromocriptine and lysuride. Like them it is a dopamine agonist intended for use with levodopa in Parkinson’s disease,1 but unlike other agonists pergolide stimulates D1 as well as D2 receptors. The manufacturer suggests that this ‘dual action’ allows ‘full expression of the effects of dopaminergic therapy’ and ‘may contribute to the therapeutic efficacy’, but the clinical relevance of differential dopamine receptor stimulation is not known.